Stay Up to Date
Breaking News,
Updates, & More
Click Here to

Is Value-Based Pricing the Solution to Unaffordable Anticancer Drugs?

TOP - February 2017, Vol 10, No 1 - Conference Correspondent

Chicago, IL—Anticancer drugs should be priced based on the value they deliver to patients, according to Peter B. Bach, MD, Physician, Epidemiologist, Researcher, and Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York.

“The prices [of anticancer drugs] have gotten to a scale that they’re actually harming the people the products are intended to help,” he said at the 4th Annual Hematology/Oncology Pharmacy Association Oncology Pharmacy Practice Management Program.

His research has found a nearly 100-fold increase in the monthly cost of anticancer drugs over the past 50 years, after adjusting for inflation. However, Dr Bach argues that drug prices should travel with their value, and if the same drug works for 2 indications but with varying degrees of efficacy, the price should vary accordingly.

To highlight the ongoing problem of rising drug prices, he developed the Evidence-Driven Drug Pricing Project (

“The goal of the project is to sift through the issues we have in drug distribution channels and payment in the quest for a system that’s more rational, where prices travel more appropriately with the attributes and benefits of drugs,” said Dr Bach.

Why Are Anticancer Drugs So Expensive?

According to Dr Bach, it is fair to ask whether the 100-fold price increase is married to a 100-fold increase in other types of improvement.

“We’re certainly making progress in cancer, so the question would be whether that rise is commensurate with the improvement in what we’re buying,” he said. However, the answer to that question is a resounding “no,” he asserted. Over the past 20 years, new drug prices have been linked to survival gain, but society has seen only diminishing returns in that space.

“Twenty years ago, the cost of a drug in terms of life years delivered (in today’s dollars) was $50,000; today it’s $250,000. So each unit of gain is costing us more than the step before,” he reported.

The pathway for a drug getting from the pharmacy to the patient involves insurance, and insurance costs have steadily risen as well. In addition to the rising cost of deductibles, coinsurance creates a burden by requiring patients to pay a percentage of the total cost of their drugs, rather than a flat copay.

“When patients are paying 10% of the price of a drug, it makes a huge difference if that drug is priced at $9 or $90,” Dr Bach pointed out.

Some argue that the United States pays more for drugs in exchange for better access, but Dr Bach refuted that argument, citing studies showing that this country spends the most per patient with cancer on drugs, even though it has the lowest penetration of anticancer drugs across the cancer population.

Another common argument is that drugs only account for approximately 10% of healthcare costs. He argued that not only is this estimate wrong, and drugs actually account for 14% to 22% of healthcare costs in the United States, but “even if it were 10%, that’s not holding.”

“For the last 3 years, the inflation rate on drug spending has exceeded that in every other major sector of healthcare. Also, 10% of healthcare is $400 billion, so it’s probably worth discussing,” he stated.

Others say that the FDA is to blame for high drug prices, but Dr Bach said this argument is implausible, stating that evidence in favor of this would be longer time to drug approval, lower approval rates, larger sample sizes, and more rigorous end points.

“But it’s the exact opposite at the FDA. Approval rates have gone up and are at epically high levels,” he said. In other words, the FDA is essentially approving everything.

Still, others argue that prices are high, but that competition will eventually correct the situation. However, Dr Bach argued that inflation catches up with any competitive effect within the first 4 months of a year.

Finally, some believe that generics will balance out high drug prices, but generic price inflation undermines that argument.

“And we know companies do things like pay for delay, evergreen their products, or do a pediatric trial in a drug that will never be used on children in order to get longer exclusivity,” he said.

“So we’ve been working on a different approach to pricing. It’s based on the idea that the current pricing system is broken, and that these solutions and problems that have been identified are false,” Dr Bach added.

The Evidence-Driven Drug Pricing Project

At the center of the Evidence-Driven Drug Pricing Project is the DrugAbacus, an interactive tool that allows users to compare the actual prices of >50 anticancer drugs to prices calculated according to value. Dr Bach calls this method “value-based pricing,” and he hopes the tool will move the discussion from an abstract idea of “value” to an actual measurable definition based on a drug’s delivered innovation and value to patients and unmet needs.

As opposed to price-fixing, this method is optional for manufacturers and users, but could pave the way toward a better drug-pricing structure.

“The trick to the DrugAbacus is that when you change how you want to price a drug, it changes it for all of the drugs at the same time. It requires cogency, the same theory around payment for all [anti]cancer drugs,” he said.

Right now, most insurers respond not to the connection of the price to the value of the drug, but purely to the price. So, in theory, appropriate pricing would also lead to the appropriate type of insurance coverage for patients.

“Value-based pricing is based on a very pure economic principle—that all goods in a marketplace should be sold at fair, appropriate prices based on what they deliver. We have so many market failures in healthcare insurers separating consumers from the true price, asymmetry of information, patients’ lack of certainty around a product and what it will do for them, but the core notion is to cut through those problems and come up with prices that make sense,” he concluded.

Related Items
Gathering and Assessing Social Determinants of Health for Improved Patient Outcomes
Meg Barbor, MPH
TOP - March 2021 Vol 14, No 2 published on March 11, 2021 in Healthcare Policy
Oncology Biosimilars: 2020 Update
Meg Barbor, MPH
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in Biosimilars
International Society of Cannabis Pharmacists Plans to Hold Inaugural Meeting in 2020
Meg Barbor, MPH
TOP - May 2020, Vol 13, No 3 published on May 21, 2020 in Medical Marijuana
Biosimilars Are Key Components of Oncology Today: Brush Up on the Basics
Meg Barbor, MPH
TOP - March 2020, Vol 13, No 2 published on March 11, 2020 in Biosimilars
Selecting Treatment for Relapsed/Refractory Multiple Myeloma in the Era of Multiple Choices
Meg Barbor, MPH
TOP - January 2020, Vol 13, No 1 published on January 10, 2020 in Hematologic Cancers
Genetic Profiling and Personalized Medicine in Myelodysplastic Syndromes
Meg Barbor, MPH
TOP - January 2020, Vol 13, No 1 published on January 10, 2020 in Hematologic Cancers
Engaging Patients in Their Cancer Care Through Digital Health
Meg Barbor, MPH
TOP - November 2019, Vol 12, No 4 published on November 7, 2019 in MASCC/ISOO Conference Highlights
Neurofeedback Reduces Symptoms of CIPN
Meg Barbor, MPH
TOP - November 2019, Vol 12, No 4 published on November 7, 2019 in MASCC/ISOO Conference Highlights
Oral Cancer and Sex in the Era of HPV Infection
Meg Barbor, MPH
Web Exclusives published on October 28, 2019 in Head and Neck Cancer
The Evolving Role of Precision Medicine in Clinical Practice
Meg Barbor, MPH
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in HOPA Abstracts
Last modified: July 22, 2021